Skip to content
HowShorted

CNS Pharmaceuticals, Inc. short interest in 2021

In 2021, CNS Pharmaceuticals, Inc.'s disclosed short interest ran from 0.85% of shares outstanding on 15 Jan 2021 to 0.92% on 31 Dec 2021, a change of +0.07 percentage points. The year's high was 2.39% on 15 Jul 2021 and its low 0.40% on 29 Jan 2021, averaging 1.37% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.47 days on 13 Aug 2021. Full history: CNS Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CNS Pharmaceuticals, Inc. in 2021

2021 in figures

Start of year
0.85% (15 Jan 2021)
End of year
0.92% (31 Dec 2021)
Change
+0.07 pp
High
2.39% (15 Jul 2021)
Low
0.40% (29 Jan 2021)
Average
1.37%
Highest days to cover
4.47 (13 Aug 2021)
SEC filings marked
5

Every report in 2021

CNS Pharmaceuticals, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20210.85%1.00
29 Jan 20210.40%1.00
12 Feb 20212.06%1.0010-K filed
26 Feb 20212.07%1.00
15 Mar 20212.04%1.67
31 Mar 20211.50%1.00
15 Apr 20211.24%2.45
30 Apr 20211.19%1.75
14 May 20211.32%2.0410-Q filed
28 May 20211.15%4.01
15 Jun 20211.17%2.23
30 Jun 20211.52%1.00
15 Jul 20212.39%1.03
30 Jul 20211.72%2.90
13 Aug 20211.53%4.4710-Q filed, results (8-K)
31 Aug 20211.53%2.37
15 Sep 20211.63%4.02
30 Sep 20211.36%1.86
15 Oct 20211.32%3.59
29 Oct 20211.18%3.07
15 Nov 20210.93%1.3710-Q filed
30 Nov 20211.08%1.00
15 Dec 20210.85%1.42
31 Dec 20210.92%1.09

See also: CNS Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.